Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

first

24 posts
SSwitzerland
Colb Becomes Switzerland’s First Provider of Pre-IPO Structured Products as Ledger-Based Securities
Read More

Colb Becomes Switzerland’s First Provider of Pre-IPO Structured Products as Ledger-Based Securities

  • 2026-08-12
Colb Asset SA operates within a Swiss-compliant legal and regulatory framework for the offering of tokenized pre-IPO structured…
RRoche
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Read More

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

  • 2026-07-24
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

  • 2026-07-23
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2,…
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-16
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
SSwitzerland
SHARP Leadership Academy Completes First International Governance Intelligence Pilot with Swiss Innovation Firm Syntezia Sàrl
Read More

SHARP Leadership Academy Completes First International Governance Intelligence Pilot with Swiss Innovation Firm Syntezia Sàrl

  • 2026-07-14
Pilot demonstrates how Ethical Infrastructure™, Governance Intelligence, and Leadership Activation can strengthen organizational trust, responsible AI governance, and…
RRoche
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Read More

Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis

  • 2026-07-14
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D  affects nearly 12…
SSwitzerland
Brilliant Earth Launches The Solstice Collection, a Limited-Edition Swiss Watch Collection and its First Entry into the Category
Read More

Brilliant Earth Launches The Solstice Collection, a Limited-Edition Swiss Watch Collection and its First Entry into the Category

  • 2026-07-09
100 Limited-Edition Pieces Mark the Brand’s 20th Anniversary and Its First Step into Horology SAN FRANCISCO, July 09,…
AAlps
Where to go in France first: 12 regions ranked from Alps to Riviera
Read More

Where to go in France first: 12 regions ranked from Alps to Riviera

  • 2026-07-06
Best for: Travellers who want a little bit of Belgium in France. Essential experience: An afternoon in Lille’s…
SSwitzerland
Possible Reasons Behind the Cancellation of Switzerland Talks
Read More

Possible Reasons Behind the Cancellation of Switzerland Talks

  • 2026-06-20
Islam Times – Perhaps the biggest analytical mistake would be to view the cancellation of the Switzerland talks…
AABB
ABB and NASCAR Unveil Sport’s First Grid Control at San Diego Weekend, Giving Fans an Unprecedented First Look at What it Takes to Power a Race
Read More

ABB and NASCAR Unveil Sport’s First Grid Control at San Diego Weekend, Giving Fans an Unprecedented First Look at What it Takes to Power a Race

  • 2026-06-19
ABB NASCAR Grid Control ABB NASCAR Grid Control gives fans a real-time peek into race control and operational…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Read More

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

  • 2026-06-02
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease…
Switzerland
www.europesays.com